JWH-011

JWH-011

IUPAC Name:	(6aR,10aR)-3-(1-naphthylmethyl)-1,2,3,6,6a,7,10,10a-octahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
Other Names:
Identifiers
CAS Number
PubChem
ChemSpider
SMILES
InChI
InChIKey
StdInChI
StdInChIKey
Properties
Chemical formula	CHNO
Appearance
Density
Melting Point
Boiling Point
Solubility
Hazards
Main Hazards
Flash Point
Autoignition Temperature

JWH-011 is a synthetic cannabinoid that was developed in the 1990s by John W. Huffman and his team at Clemson University. It is part of a series of compounds that were created to study the structure-activity relationships of cannabinoids, which are compounds that interact with the cannabinoid receptors in the brain and body.

Chemical Structure and Properties

JWH-011 is a member of the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthyl group attached to an indole core, which is a common feature among many synthetic cannabinoids. The compound has a molecular formula of C24H26O and a molar mass of 330.47 g/mol.

Pharmacology

JWH-011 acts as a potent agonist at the CB1 receptor, which is primarily found in the central nervous system, and the CB2 receptor, which is primarily found in the peripheral tissues. The activation of these receptors by JWH-011 can lead to a variety of effects, including alterations in mood, perception, and cognition, similar to those produced by tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Research and Applications

JWH-011, like other synthetic cannabinoids, has been used in scientific research to better understand the endocannabinoid system and the role of cannabinoid receptors in health and disease. These studies have provided insights into potential therapeutic applications of cannabinoids, such as in the treatment of pain, inflammation, and neurological disorders.

Legal Status

The legal status of JWH-011 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. The compound has been included in various legislative acts aimed at controlling synthetic cannabinoids and preventing their misuse.

Safety and Toxicity

The safety profile of JWH-011 is not well-established, as it has not been extensively studied in humans. However, synthetic cannabinoids as a class have been associated with a range of adverse effects, including anxiety, paranoia, tachycardia, and in some cases, severe toxicity leading to hospitalization.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• Endocannabinoid system
• Tetrahydrocannabinol